Search Results

NImmune Biopharma, (“NImmune”), announced that it will present three abstracts, including final Phase 2 data for omilancor in active Ulcerative Colitis patients at the American College of Gastroenterology (“ACG”) 2023 Annual Scientific Meeting (“ACG 2023”).

October 23, 2023

·

10 min read

BioCapital

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

NImmune Biopharma will be presented at the American College of Rheumatology’s (ACR) annual meeting. ACR Convergence 2023 will take place from November 10-15, 2023, at the San Diego Convention Center in San Diego, California, with NImmune’s poster presentation to take place on Tuesday, November 14 from 9:00 am – 11:00 am.

November 14, 2023

·

7 min read

Press Releases

The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science

January 13, 2025

·

7 min read

Press Releases

The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic Control of Systemic Lupus Erythematosus in the Journal of Immunology

October 8, 2024

·

7 min read

Drug Development

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

NImmune Biopharma today announced Phase 2 data on an approvable population of ulcerative colitis (UC) patients and its plans to initiate a registration directed global Phase 3 program for omilancor for the treatment of UC.

May 17, 2023

·

9 min read

BioCapital

NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline

NImmune Biopharma today announced the launch of a research collaboration with the NIMML Institute (“NIMML”), a nonprofit institute dedicated to the discovery of novel immune-mediated precision medicines.

May 3, 2023

·

4 min read